M. A. Dzhelialova

M. A. Dzhelialova

Auto-generated profile, based on publicly available information

M. A. Dzhelialova

N.N. Petrov National Medical Research Center of Oncology

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2020 in Meditsinskiy sovet = Medical Council
Verified
Journal Article
Open access
PDF file
VSV. F. Semiglazov
V. F. Semiglazov
MDM. A. Dzhelialova
M. A. Dzhelialova
SYS. S. Yerechshenko
S. S. Yerechshenko
EME. T. Munaeva
E. T. Munaeva
RPR. S. Pesotsky
R. S. Pesotsky
ПКП. В. Криворотько
П. В. Криворотько
Achieving a pathologic complete response as a result of neoadjuvant treatment is associated with improved prognosis in breast cancer. The CREATE-X trial showed a significant survival improvement with capecitabine treatment of patients with residual invasive disease following neoadjuvant chemotherapy, and the KATHERINE trial demonstrated a significant benefit of trastuzumabemtansine (TDM1) in patients with HER2-positive breast cancer who did not achieve a pathologic complete response, so we have a lot of interesting alternatives of post-neoadjuvant treatments for high-risk patients. The discovery of molecular markers of resistance to endocrinotherapy (cyclin-dependent kinases (CDK 4/6), ER mutation (ESR1), mTOR signaling pathway, co-expression of ER+/HER2+) and inhibitors to them expanded the possibilities of endocrinotherapy not only in advanced and metastatic breast cancer, but also in residual ER+ tumors. The pCR rates in hormone receptor-positive breast cancer after neoadjuvant chemotherapy are around 10%, which is much lower than the values observed in HER2-positive and triple negative subtypes, so new strategies are needed to improve pCR rates in this subgroup, even though the adjuvant endocrine therapy impacts significantly the outcomes of this patients. The cyclin-dependent kinases (CDKs) are serine–threonine kinases that regulate cell cycle progression from the G1 to the S-phase during mitosis. CDKs activity can be abnormally increased or dysregulated in breast cancer, leading to a constant stimulus for cell proliferation and survival, which is a known mechanism of resistance to endocrine treatment. The CDK inhibitors act on CDKs and block their activity, thereby restoring the cell cycle regulation. In studies with metastatic hormone receptor-positive breast cancer patients, the combination of a CDKis with first or second-line endocrine therapy showed significant improvements in progression-free survival and response rates. Evolving techniques such as next-generation sequencing and gene expression profiles have improved our understanding of the biology of residual disease and also the mechanisms involved in treatment resistance.

1 October 2026 in Medical alphabet
Verified
Journal Article
Open access
PDF file
MDM. A. Dzhelialova
M. A. Dzhelialova
AZA. E. Zolotukhina
A. E. Zolotukhina
ASAndrey Vladimirovich Shalaev
Andrey Vladimirovich Shalaev
RDR. V. Donskikh
R. V. Donskikh
PKP. V. Krivorotko
P. V. Krivorotko
АМА. В. Малек
А. В. Малек
Hormone receptor–positive (HR+) breast cancer is the most common subtype of the disease and is characterized by significant heterogeneity in its clinical course and response to therapy. Adjuvant endocrine therapy with aromatase inhibitors represents a highly effective alternative to chemotherapy in postmenopausal patients, demonstrating comparable clinical response rates with lower toxicity. Despite the proven efficacy of neoadjuvant endocrine therapy (NET) in reducing tumor volume and increasing the rate of breast-conserving surgery, the rate of pathological complete response (pCR) in HR+/HER2– breast cancer remains low (10–20%). Predicting which patients with breast cancer will respond to treatment remains a challenging task. This limited predictive capability often leads to the use of multiple lines of therapy in the search for an option that will provide a therapeutic response. In this context, biomarkers of treatment efficacy, including Ki‑67 index dynamics, the Preoperative Endocrine Prognostic Index (PEPI), and multigene panels, are particularly important. In recent years, the molecular mechanisms of endocrine resistance have been actively investigated, including ESR1 gene mutations, activation of the PI3K/AKT/mTOR signaling pathways, and alterations in cell cycle regulation. Post-transcriptional regulation of gene expression involving microRNAs plays a significant role in these processes. Specific microRNAs (in particular, miR‑221/222, miR‑21, and miR‑342) have demonstrated an association with sensitive ty or resistance to endocrine therapy and are considered potential predictive biomarkers. Of particular interest is the analysis of circulating microRNAs, which may be used as minimally invasive markers for dynamic monitoring of treatment response and early detection of endocrine resistance. Thus, the integration of clinical, morphological, and molecular parameters, including microRNA profiling, represents a promising approach for personalizing neoadjuvant endocrine therapy and optimizing treatment strategies in patients with HR+ breast cancer.